^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

    Published date:
    12/01/2021
    Excerpt:
    The combination of lenvatinib and everolimus is FDA- and EMA-approved after TKI failure [II, B; ESMO-MCBS v1.1 score: 4] and could be considered following progression after first-line TKI monotherapy or a TKI in combination with an immune checkpoint inhibitor [IV, C].
    Secondary therapy:
    everolimus
    DOI:
    https://doi.org/10.1016/j.esmoop.2021.100304
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/03/2021
    Excerpt:
    Subsequent Therapy for Clear Cell Histology...Preferred Regimens...Lenvatinib + everolimus was changed to a category 2A recommendation.
    Secondary therapy:
    everolimus